
Release date: 2024-08-08 15:49:29 Article From: Lucius Laos Recommended: 266
Exkivity is a new type of targeted therapy for lung cancer, which is a third representative of the cortical growth factor receptor (EGFR) inhibitor, and is a new generation of potent and selective small molecule tyrosine kinase inhibitors, which has shown remarkable effects in the treatment of lung cancer.
Exkivity broadly inhibits a variety of mutant kinases on lung cells, especially against EGFR exon 20 insertion mutations and HER2 mutations, with a high degree of targeting and precision. This property allows Exkivity to effectively inhibit the growth and spread of cancer cells when treating patients with non-small cell lung cancer (NSCLC) with specific gene mutations, thereby controlling tumor progression.
The results of the clinical trial showed that Exkivity performed well in prolonging progression-free survival and overall survival in lung cancer patients, resulting in a better prognosis for patients. In addition, the drug can also significantly improve the patient's symptoms, such as dyspnea, cough, etc., and improve the patient's quality of life. Compared to traditional chemotherapy drugs or other targeted therapies, Exkivity has relatively low side effects and is better tolerated by patients, which makes long-term treatment possible.
It should be noted that patients should use Exkivity under the guidance of their doctor, follow the doctor's instructions, and not change the dosage and method of administration on their own.
To effectively prevent non-small cell lung cancer, you can start with the following aspects:
For diagnosed chronic lung diseases, such as chronic obstructive pulmonary disease, tuberculosis, pulmonary sarcoidosis, etc., standardized treatment should be received as soon as possible to control the progression of the disease and reduce its long-term impact on lung health.
Smoking is a major risk factor for non-small cell lung cancer, so you should quit smoking firmly and avoid exposure to secondhand smoke for long periods of time.
Especially for high-risk groups, such as long-term smokers, people with a family history of lung cancer, etc., regular lung health examinations should be carried out in order to detect lesions early and deal with them in time.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1722025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1642025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: